Sage Therapeutics has priced the oral postpartum depression pill it developed with partner Biogen at $15,900 for a full 14-day course of treatment, the company said on Tuesday.
The two companies have been the primary beneficiaries of the global boom in obesity drugs, ballooning their market values and reshaping expectations not just in the healthcare industry, but also for sellers of sugary snacks, nutritional aids and packaged foods.